The Center for Clinical Epidemiology and Biostatistics (CCEB) of the University of Pennsylvania (Penn) School of Medicine submits this renewal application to continue and expand an innovative and successful post- doctoral training program in clinical pharmacoepidemiology (i.e., the use and effects of medications in populations). Penn promotes an academic environment in which basic and clinical research are encouraged and viewed as attractive career paths for trainees. This training program attracts clinical pharmacoepidemiology trainees from other institutions nationwide. It is anticipated that many graduates of this training program will be placed in other institutions nationwide, resulting in a program of the highest impact. The two- to three-year training program consists of required courses in clinical epidemiology, research methodology, biostatistics, pharmacoepidemiology, pharmacokinetics;elective courses in pharmacology, pharmacy practice, or other areas relevant to the trainees'interests and experience;extensive independent readings;participation in research seminars at the CCEB;clinical experiences in clinical pharmacology;and the completion of a mentored independent research project in clinical pharmacoepidemiology. The program is designed to: 1) train clinicians to be rigorous and independent academic investigators able to use the range of approaches available in epidemiology to address research issues in clinical pharmacoepidemiology related to the etiology, prognosis, prevention and early detection, treatment, clinical economics, technology assessment, medical decision making, and quality of patient care;2) provide an understanding of the basic principles of clinical pharmacology;3) provide intensive, supervised research experience with mentors in clinical pharmacoepidemiology;4) provide closely mentored research experiences with faculty preceptors in clinical pharmacoepidemiology;and 5) strengthen the links between traditional epidemiology and clinical pharmacology. With the expansion of this training program, five fellowship slots will be awarded each year. Trainees matriculate in the Master of Science in Clinical Epidemiology (MSCE) degree program. Strengths of the proposed program are: 1) the large pool of extremely strong candidates seeking training in pharmacoepidemiology;2) the long history of successful research training programs in the CCEB, including the internationally renowned clinical pharmacoepidemiology program and overlapping training in comparative effectiveness research (a new area of interest to NIH);3) the comprehensive course offerings and research programs available to trainees;and 4) the successful training records of the program directors and faculty. In addition, the availability of the CCEB faculty, who provide expertise in a wide range of disciplines;numerous large databases useful for research projects and training;a broad array of specialized analytic capabilities available for clinical studies (e.g., clinical trials, case-control, cohort research, etc.);and the faculties'commitment to collaborative research and training, combine to provide an ideal environment for this program.

Public Health Relevance

There is a major national shortage of qualified clinicians able to conduct rigorous research in clinical pharmacoepidemiology. There is a particular shortage of clinical investigators focusing on drug safety and comparative effectiveness research. This training program addresses this shortage through the efforts of distinguished training program faculty. This is an outstanding competitive renewal for a program set within an institution with excellent research resources and focus. The investigators are outstanding and the trainees have been productive and successful.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Special Emphasis Panel (ZGM1-BRT-5 (PD))
Program Officer
Okita, Richard T
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Mehta, Jimish M; Haynes, Kevin; Wileyto, E Paul et al. (2014) Comparison of prior authorization and prospective audit with feedback for antimicrobial stewardship. Infect Control Hosp Epidemiol 35:1092-9
Horton, Daniel B; Strom, Brian L; Putt, Mary E et al. (2014) A55: Clostridium difficile Infection-Associated Reactive Arthritis in a Pediatric Cohort. Arthritis Rheumatol 66 Suppl 11:S82
Ogdie, Alexis; Haynes, Kevin; Troxel, Andrea B et al. (2014) Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study. Ann Rheum Dis 73:149-53
Callis Duffin, K; Yeung, H; Takeshita, J et al. (2014) Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice. Br J Dermatol 170:672-80
Takeshita, Junko; Callis Duffin, Kristina; Shin, Daniel B et al. (2014) Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. J Am Acad Dermatol 71:633-41
Takeshita, Junko; Mohler, Emile R; Krishnamoorthy, Parasuram et al. (2014) Endothelial cell-, platelet-, and monocyte/macrophage-derived microparticles are elevated in psoriasis beyond cardiometabolic risk factors. J Am Heart Assoc 3:e000507
Ogdie, Alexis; Alehashemi, Sara; Love, Thorvardur Jon et al. (2014) Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the health improvement network. Pharmacoepidemiol Drug Saf 23:918-22
Yeung, Howa; Takeshita, Junko; Mehta, Nehal N et al. (2013) Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol 149:1173-9
Munson, Jeffrey C; Kreider, Maryl; Chen, Zhen et al. (2010) Factors associated with the use of corticosteroids in the initial management of idiopathic pulmonary fibrosis. Pharmacoepidemiol Drug Saf 19:756-62
Munson, Jeffrey C; Kreider, Maryl; Chen, Zhen et al. (2010) Effect of treatment guidelines on the initial management of idiopathic pulmonary fibrosis. Br J Clin Pharmacol 70:118-25

Showing the most recent 10 out of 14 publications